InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by ALICE ROUDOT-KETELERS, Chief Operating Officer. Officer active across 1 companies, notably INVENTIVA. Cumulatively, 4 disclosures have been recorded. The latest transaction was disclosed on 7 January 2026 — ACQUISITION ACTIONS GRATUITES. Regulator: AMF. All data is accessible without signup.
Declarations4 total
025,000 shares0
ActionHors plateforme de négociation
2026DD1088249·
Ideal exit: 4 Oct 2026 (T+270)
030,000 shares0
ActionHors plateforme de négociation
2024DD1012792·
Ideal exit: 22 Sept 2025 (T+270)
021,500 shares0
ActionHors plateforme de négociation
2024DD959502·
Ideal exit: 31 Dec 2024 (T+270)
015,000 shares0
ActionHors plateforme de négociation
2023DD941947·
Ideal exit: 3 Sept 2024 (T+270)
4 of 4 declarations
About ALICE ROUDOT-KETELERS
Alice Roudot-Ketelers serves as Chief Operating Officer at Inventiva, following earlier responsibilities as Vice President Pharmaceutical & Clinical Development. Her career is rooted in the biopharmaceutical industry and spans more than 20 years of experience in clinical and pharmaceutical development. This background is especially relevant in an innovation-driven company such as Inventiva, where operational discipline and scientific execution are critical to advancing late-stage drug development programs. At Inventiva, she has been responsible for leading and overseeing the company’s global clinical and pharmaceutical development activities, including work tied to lanifibranor and the pivotal Phase III NATiV3 trial in NASH. Prior to joining Inventiva in 2021, Alice Roudot-Ketelers served as Vice President Clinical Development at Genfit from June 2014 to July 2021. There, she was in charge of all drug development programs and oversaw cross-functional teams spanning Chemistry, Manufacturing and Controls (CMC), non-clinical development, and clinical development through Phase III. That role gave her deep experience in managing complex development portfolios, aligning multidisciplinary teams, and executing programs within the regulatory and operational constraints of a listed biotech environment. Her move to Inventiva, announced in September 2021, came at a strategic moment as the company accelerated development of its pipeline and strengthened its operational capabilities in France and internationally. Her appointment as COO in February 2023 confirmed her central role in shaping and delivering the company’s development priorities. With academic training in pharmacy, including a Doctor of Pharmacy degree from the University of Lille and a master’s degree in pharmacy from the University of Lyon, she combines scientific expertise, clinical development know-how, and strong operational leadership. This makes her a key executive in the management of complex clinical programs within a high-growth publicly listed biopharmaceutical company.
